VANCOUVER, BRITISH COLUMBIA--(Marketwire - Sept. 12, 2007) - Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, announced today that enrolment has commenced in a Phase II clinical trial evaluating Allon’s product AL-108 as a treatment for schizophrenia-related cognitive impairment. This study is being conducted in collaboration with TURNS (Treatment Units for Research on Neurocognition and Schizophrenia) and with support from the National Association for Research in Schizophrenia and Affective Disorders (NARSAD).
